Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지

Effect of protein transduction domain fused-bone morphogenetic protein-2 on bone regeneration in rat calvarial defects

단백질 전달 영역 융합-Bone Morphogenetic Protein-2가 백서 두개골 결손부에서 골 조직 재생에 미치는 효과

  • Um, Yoo-Jung (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University) ;
  • Cho, Kyoo-Sung (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University) ;
  • Kim, Chong-Kwan (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University) ;
  • Choi, Seong-Ho (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University) ;
  • Chai, Jung-Kiu (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University) ;
  • Kim, Chang-Sung (Department of Periodontology, Oral Science Research Center, College of Dentistry, Yonsei University)
  • 엄유정 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 조규성 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 김종관 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 최성호 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 채중규 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 김창성 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Recombining bone morphogenetic protein (BMP) is usually acquiredfrom high level animals. Though this method is effective, its high cost limits its use. The purpose of this study was to evaluate the effect of bone morphogenetic protein-2 with protein transduction domain (BMP-2/PTD;TATBMP-2) on bone regeneration. Rat calvarial defect model and osteoblastic differentiation model using MC3T3 cell were used for the purpose of the study. Materials and Methods: MC3T3 cells were cultured until they reached a confluence stage. The cells were treated with 0, 0.1, 1, 10, 100, 500 ng/ml of BMP-2/PTD for 21 days and at the end of the treatment, osteoblastic differentiation was evaluated usingvon Kossa staining. An 8mm, calvarial, critical-size osteotomy defect was created in each of 48 male Spraque-Dawley rats (weight $250{\sim}300\;g$). Three groups of 16 animals each received either BMP-2/PTD (0.05mg/ml) in a collagen carrier, collagen only, or negative surgical control. And each group was divided into 2 and 8 weeks healing intervals. The groups were evaluated by histologic analysis(8 animals/group/healing intervals) Result: In osteoblastic differentiation evaluation test, a stimulatory effect of BMP-2/PTD was observed in 10ng/ml of BMP-2/PTD with no observation of dose-dependent manner. The BMP-2/PTD group showed enhanced local bone formation in the rat calvarial defect at 2 weeks. New bone was observed at the defect margin and central area of the defect. However, new bone formation was observed only in 50% of animals used for 2weeks. In addition, there was no new bone formation observed at 8 weeks. Conclusion: The results of the present study indicated that BMP-2/PTD(TATBMP-2) have an positive effect on the bone formation in vitro and in vivo. However, further study should be conducted for the reproducibility of the outcomes.

Keywords

References

  1. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899 https://doi.org/10.1126/science.150.3698.893
  2. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: Molecular clones and activities. Science 1988;242:1528-1534 https://doi.org/10.1126/science.3201241
  3. Celeste AJ, Iannazzi JA, Taylor RC, et al. Identification of transforming growth factor-family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci U S A 1990;87:9843-9847
  4. Kim CS, Choi SH, Choi BK, et al. The effect of recombinant human bone morphogenetic protein-4 on the osteoblastic differentiation of mouse calvarial cells affected by Porphyromonas gingivalis. J Periodontol 2002;73:1126-1132 https://doi.org/10.1902/jop.2002.73.10.1126
  5. Wikesjo UM, Guglielmoni P, Promsudthi A, et al. Periodontal repair in dogs: effect of rhBMP-2 concentration on regeneration of alveolar bone and periodontal attachment. J Clin Periodontol 1999;26:392-400 https://doi.org/10.1034/j.1600-051X.1999.260610.x
  6. Kingsley DM, Bland AE, Grubber JM, et al. The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF superfamily. Cell 1992;71:399-410 https://doi.org/10.1016/0092-8674(92)90510-J
  7. Solloway MJ, Dudley AT, Bikoff EK, et al. Mice lacking BMP-6 function. Dev Genet 1998;22:321-323 https://doi.org/10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8
  8. Jena N, Martin-Seisdedos C, McCue P, et al. BMP7 null mutation in mice: Developmental defects in skeleton, kidney, and eye. Exp Cell Res 1997;230:28-37 https://doi.org/10.1006/excr.1996.3411
  9. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteo-genic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-20362
  10. Wang EA, Rosen V, D'Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990;87:2220-2224 https://doi.org/10.1073/pnas.87.6.2220
  11. Cook SD, Salkeld SL, Patron LP. Bone defect healing with an osteogenic protein-1 device combined with carboxymethylcellulose. J Biomed Mater Res Appl Biomater 2005;75:137-145
  12. Cook SD, Baffes GC, Wolfe MW, et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am 1994;176:827-838
  13. Cook SD, Wolfe MW, Salkeld SL, Rueger DC. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 1995;77:734-750 https://doi.org/10.2106/00004623-199505000-00010
  14. Reddi AH. Bone Morphogenetic Proteins: From Basic Science to Clinical Applications. J Bone Joint Surg Am 2001;83:S1 - S6 https://doi.org/10.1302/0301-620X.83B1.11892
  15. Griffith DL, Keck PC, Sampath TK, et al. Three- dimensional structure of recombinant human osteogenic protein 1 : Structural paradigm for the transforming growth factor superfamily. Proc Natl Acad Sci USA 1996;93:878-883
  16. Hong SJ, Kim CS, Jung UW, et al. Fibrin-Fibronectin Sealing System in Combination with -Tricalcium Phosphate as a Carrier for Recombinant Human Bone Morphogenetic Protein-2: Effects on Bone Formation in Rat Calvarial Defects. Biomaterials 2005;27:3810-3816 https://doi.org/10.1016/j.biomaterials.2006.02.045
  17. Hyun SJ, Choi SH, Chai JK, et al. The effect of recombinant human bone morphogenetic protein-2, 4 and 7 on bone formation in rat calvarial defects. J Periodontol 2005;76:1-8 https://doi.org/10.1902/jop.2005.76.1.1
  18. Choi SH, Kim CK, Cho KS, et al. Effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) on healing in 3-wall intrabony defects in dogs. J Periodontol 2002;73:63-72 https://doi.org/10.1902/jop.2002.73.1.63
  19. Pang EK, Im SU, Kim CS, et al. Effect of recombinant human bone morphogenetic protein-4 dose on bone formation in rat calvarial defects. J Periodontol 2004;75:1364-1370 https://doi.org/10.1902/jop.2004.75.10.1364
  20. Ahn SH, Kim CS, Suk HJ, et al. Effect of Recombinant Human Bone Morphogenetic Protein- 4 with Carriers in Rat Calvarial Defects. J Periodontol 2003;74:787-797 https://doi.org/10.1902/jop.2003.74.6.787
  21. Frankel AD, Pabo CO. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 1988;55:1189 -1193 https://doi.org/10.1016/0092-8674(88)90263-2
  22. Watson K, Edwards RJ. HIV-1-trans-activating(TAT) protein both a target and a tool in therapeutic approaches. Biochem Pharmacol 1999;58:1521-1528 https://doi.org/10.1016/S0006-2952(99)00209-9
  23. Lindgren M, Halbrink M, Prochiantz A, Langel U. Cell penetrating peptides. Trends Pharmacol Sci 2000;21:99-103 https://doi.org/10.1016/S0165-6147(00)01447-4
  24. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction : unrestricted delivery into all cell? Trends cell Biol 2000;10:290-295 https://doi.org/10.1016/S0962-8924(00)01771-2
  25. Schwarze SR, Dowdy SF. In vivo protein transduction : intercellular delivery of biological active proteins. componds and DNA. Trends Pharmacol Sci 2000;21:45-48 https://doi.org/10.1016/S0165-6147(99)01429-7
  26. Fawell S, Seery J, Daikh Y, et al. TAT- mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-668 https://doi.org/10.1073/pnas.91.2.664
  27. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full- length TAT union proteins into mammalian cells: TAT -p27Kip1 induces cell migration. Nat Med 1998;4:1449-1452 https://doi.org/10.1038/4042
  28. Jung SW, Kim NH, Yook JI, et al. Bone regenerative effects of recombinant human bone morphogentic protein-2 employed protein transduction domain. J Korean Acad Periodontol 2007;37:497-509 https://doi.org/10.5051/jkape.2007.37.3.497
  29. Han DK, Kim CS, Cho KS. Effect of a Fibrin-fibronectin sealing system as a carrier for recombinant human bone morphogenetic protein-4 on bone formation in rat calvarial defects. J Periodontol 2005;76:2216-2222 https://doi.org/10.1902/jop.2005.76.12.2216
  30. Kim CS, Kim JI, Kim J, et al. Ectopic bone formation associated with recombinanthuman bone morphogenetic protein-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers. Biomaterials 2004;19:1-7
  31. Urist MR, Lietze A, Dawson E. Beta-tricalcium phosphate delivery system for bone morphogenetic protein. Clin Orthop 1984;187:277-280
  32. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibulofacial nonunion. Clin Orthop 1986;205:299-308
  33. King GN, Cochran DL. Factors that modulate the effect of bone morphogenetic protein-induced periodontal regeneration; a critical review. J Periodontol 2002;73:925-936 https://doi.org/10.1902/jop.2002.73.8.925
  34. Yasco AW, Lane JM, Fellinger EJ. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). J Bone Joint Surg Am 1992;74-A:659-671
  35. Barboza EP, Duarte ME, Geolas L, et al. Ridge augmentation following implantation of recombinant human bone morphogenetic protein-2 in the dog. J Periodontol 2000;71:488-496 https://doi.org/10.1902/jop.2000.71.3.488
  36. Frankel AD, Pabo CO. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 1988;55:1189 -1193 https://doi.org/10.1016/0092-8674(88)90263-2
  37. Maurice Green, and Paul M. Loewenstein. Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat Trans-Activator Protein. Cell 1988;55:1179-1188 https://doi.org/10.1016/0092-8674(88)90262-0
  38. Ford KG, Souberbielle BE, Darling D, Farzaneh F. Protein transduction: an alternative to genetic intervention? Gene therapy 2001;8:1-4 https://doi.org/10.1038/sj.gt.3301383
  39. Leifert LA, Whitton JL. "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanism. Mol Ther 2003;8:13-20 https://doi.org/10.1016/S1525-0016(03)00151-5
  40. Ozkaynak E, Rueger DC, Drier EA, et al. Op-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J 1990;9:2085-2093
  41. Takakis DN, Koh A, Jin L, et al. Peri-implant bone regenerationusing recombinant human bone morphogenetic protein-2 in a canine model: A dose-response study. J Periodontal Res 2002;37:93-100 https://doi.org/10.1034/j.1600-0765.2002.00021.x
  42. Sandhu HS, Kanim LE, Kabo JM, et al. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996;21:2115-2122 https://doi.org/10.1097/00007632-199609150-00012
  43. Jehangir SW, Radu VS, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nature medicine 2004;10:311-315